NEW YORK (GenomeWeb) – Vermillion said today that Medi-Cal, California's Medicaid program, now supports the company's OVA1 ovarian cancer test in its medical policy guidelines.

According to Vermillion, Medi-Cal covers more than 12.6 million lives, or roughly a third of the covered lives in California.

OVA1 measures levels of five proteins in patient blood and is intended for triaging patients with ovarian adnexal masses as part of preoperative evaluations to determine the likelihood that a mass is cancerous.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.